nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

21. Amyloidose

verfasst von : Lars Hagmeyer, Ute Hegenbart, Stefan Schönland, Björn Kleibrink, Helmut Teschler

Erschienen in: Seltene Lungenerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Unter dem Begriff Amyloidose wird eine heterogene Gruppe von Erkrankungen zusammengefasst, bei denen unterschiedliche Proteine in unlöslicher Form deponiert werden und dadurch die umgebenden Strukturen und Organe schädigen. Jedes Vorläuferprotein, das Amyloid bilden kann, induziert ein charakteristisches Muster des Organbefalls und typische Krankheitsbilder mit variabler Ausprägung. Bei Autopsien finden sich oft Amyloidablagerungen in verschiedenen Kompartimenten der Lunge, doch sind diese nicht immer mit Krankheitssymptomen verbunden. Der Nachweis einer Amyloidose geschieht histologisch mithilfe der Kongorotfärbung, die Identifizierung des zugrunde liegenden Proteins mit immunologischen Methoden in spezialisierten Zentren. Kontaktdaten finden sich im Internet und sind in diesem Beitrag tabellarisch zusammengefasst. Für die weitere Abklärung und die Erstellung eines Behandlungsplans existieren klinische Pfade und Empfehlungen, die dieser Beitrag in Form von Abbildungen, Tabellen und Literaturangaben zur Verfügung stellt. Alle Patienten mit Amyloidose sollten von einem dieser Zentren (mit)betreut werden, da die Expertise von prognostischer Bedeutung ist und generell bei seltenen Erkrankungen zentralisierte Forschung unser Handeln zum Wohle der aktuell und zukünftig Erkrankten bestimmen sollte.

Ayuso MC, Gilabert R, Bombi JA, Salvador A (1987) CT appearance of localized pulmonary amyloidosis. J Comput Assist Tomogr 11:197–199PubMedCrossRef

Basset M, Hummedah K, Kimmich C et al (2020) Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression. Am J Hematol. (im Druck). https://doi.org/10.1002/ajh.25915

de Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GRV, Pepys MB (1982) Serum amyloid A protein (SAA) concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet ii:231–234CrossRef

Benson M et al (2018) Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 25:215–219PubMedCrossRef

Berg AM, Troxler RF, Grillone G et al (1993) Localized amyloidosis of the larynx: evidence for light chain composition. Ann Otol Rhinol Laryngol 102:884PubMedCrossRef

Berk JL, O’Regan A, Skinner M (2002) Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med 23:155–166PubMedCrossRef

Berk JL, Keane J, Seldin DC (2003) Persistent pleural effusions in primary systemic amyloidosis. Chest 124:969–977PubMedCrossRef

Blake CCF, Serpell LC (1996) Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous b-sheet helix. Structure 4:989–998PubMedCrossRef

Brandelik SC, Heussel CP, Kauczor HU et al (2020) CT features in amyloidosis of the respiratory system – Comprehensive analysis in a tertiary referral center cohort. Eur J Radiol 129:109123PubMedCrossRef

Buxbaum J (1992) Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 6:323–346PubMedCrossRef

Carbone JE, Barker D, Stauffer JL (1985) Sleep apnea in amyloidosis. Chest 87:401–403PubMedCrossRef

Celli BR, Rubinow A, Cohen AS, Brody JS (1978) Patterns of pulmonary involvement in systemic amyloidosis. Chest 74(5):543–554PubMedCrossRef

Chow LT, Chow W, Shum D (1993) Fatal massive upper respiratory tract haemorrhage: an unusual complication of localised amyloidosis of the larynx. J Laryngol Otol 107:51–53PubMedCrossRef

Cordier JF, Loire R, Brune J (1986) Amyloidosis of the lower respiratory tract. Clinical and pathologic features in a series of 21 patients. Chest 90:827–831PubMedCrossRef

Cotton RE, Jackson JW (1964) Localised tumours of the lung simulating neoplasm. Thorax 19:97–103PubMedPubMedCentralCrossRef

Dahl KA, Kernstine KH, Vannatta TL, Karwal MW, Thomas KW, Schraith DS (2004) Tracheobronchial amyloidosis: A surgical disease with long-term consequences. J Thorac Cardiovasc Surg 128:789–792PubMedCrossRef

Delevaux I, Andre M, Amoura Z, Kemeny JL, Piette JC, Aumaitre O (2001) Concomitant diagnosis of primary Sjogren’s syndrome and systemic AL amyloidosis. Ann Rheum Dis 60:694–695PubMedPubMedCentralCrossRef

Dingli D, Utz JP, Gertz MA (2001) Pulmonary arterial hypertension in patients with amyloidosis. Chest 120:1735–1738PubMedCrossRef

Dubrey SW, Cha K, Anderson J (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. Q J Med 91:141–157CrossRef

Elghetany MT, Saleem A, Barr K (1989) The congo red stain revisited. Ann Clin Lab Sci 19:190–195PubMed

Gallego F, Canelas J (1974) Hilar enlargment in amyloidosis. N Engl J Med 291:531CrossRef

Gertz MA, Kyle RA (1988) Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 85:73–80PubMedCrossRef

Gillmore JD, Hawkins PN (1999) Amyloidosis and the respiratory tract. Thorax 54:444–451PubMedPubMedCentralCrossRef

Gillmore JD, Hawkins PN (2013) Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol 9:574–586PubMedCrossRef

Gillmore JD, Wechalekar A, Bird J et al (2015) Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 168:207–218. (BCSH Committee)PubMedCrossRef

Griepp PR, Kyle RA, Bowie EJW (1981) Factor X deficiency in amyloidosis: a critical review. Am J Hematol 11:443–450CrossRef

Grogg KL, Aubry MC, Vrana JA et al (2013) Nodular pulmonary amyloidosis is characterized by localized immunoglobulin deposition and is frequently associated with an indolent B-cell lymphoproliferative disorder. Am J Surg Pathol 37:406–412PubMedCrossRef

Gross B (1981) Radiographic manifestations of lymph node involvement in amyloidosis. Radiology 138:11–14PubMedCrossRef

Hamidi AK, Leipnieks JJ, Nakamura A, Benson MD (1999) Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 162:5556–5560

Hawkins PN (1994) Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci 87:289–295CrossRef

Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323:508–513PubMedCrossRef

Howard S, Jagannathan J, Krajewski K et al (2012) Multimodality imaging in amyloidosis. Cancer Imaging 27(12):109–117CrossRef

Hui AN, Koss MN, Hochholzer L, Wehunt WD (1986) Amyloidosis presenting in the lower respiratory tract. Clinicopathologic, radiologic, immunohistochemical, and histochemical studies on 48 cases. Arch Pathol Lab Med 110:212–218PubMed

Jeong Y, Lee K, Chung MP (2004) Amyloidosis and lymphoproliferative disease in Sjogren syndrome thin-section comuted tomography findings and histopathologic comparisions. J Comput Assist Tomogr 28:776–781PubMedCrossRef

Khor YM, Cuddy S, Harms HJ et al (2020) Quantitative (18F)florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging 47:1998–2009PubMedCrossRef

Kiuru S, Nieminen T, Partinen M (1999) Obstructive sleep apnoea syndrome in hereditary gelsolin-related amyloidosis. J Sleep Res 8:143–149PubMedCrossRef

Koss MN, Holchholzer L, Moran CA, Frizzera G (1998) Pulmonary plasmacytomas: a clinicopathologic and immunohistochemical study of five cases. Ann Diagn Pathol 2:1–11PubMedCrossRef

Kurrus JA, Hayes JK, Hoidal JR, Menendez MM, Elstad MR (1998) Radiation therapy for tracheobronchial amyloidosis. Chest 114:1489–1492PubMedCrossRef

Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59PubMed

Lachmann HJ, Hawkins PN (2003) Novel pharmacological strategies in amyloidosis. Nephron Clin Pract 94:c85–c88PubMedCrossRef

Lachmann HJ, Hawkins PN (2006) Amyloidosis and the lung. Chron Respir Dis 3:203–214PubMedCrossRef

Lachmann HJ, Booth DR, Booth SE (2002a) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346:1786–1791PubMedCrossRef

Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB (2002b) Unicentric Castleman’s disease complicated by systemic AA amyloidosis: a curable disease. Q J Med 95:211–218CrossRef

Lesser A (1877) Ein Fall von Enchondroma osteoides mixtum der Lunge mit partieller Amyloidverortung. Virchow’s Arch (Palhol Anat) 69:404–408CrossRef

Lesser BA, Leeper KV Jr, Conway W (1988) Obstructive sleep apnea in amyloidosis treated with nasal continuous positive airway pressure. Arch Intern Med 148:2285–2287PubMedCrossRef

Lewis JE, Olsen KD, Kurtin PJ, Kyle RA (1992) Laryngeal amyloidosis: a clinicopathologic and immunohistochemical review. Otolaryngol Head Neck Surg 106:372–377PubMedCrossRef

Linke RP, Gärtner HV, Michels H (1995) High-sensitivity diagnosis of AA amyloidosis using Congo red and immunohistochemistry detects missed amyloid deposits. J Histochem Cytochem 43:863–869PubMedCrossRef

Livneh A, Shtrasburg S, Martin BM, Baniel J, Gal R, Pras M (2001) Light chain amyloidosis of the urinary bladder. A site restricted deposition of an externally produced immunoglobulin. J Clin Pathol 54:920–923PubMedPubMedCentralCrossRef

Lovat LB, Pepys MB, Hawkins PN (1997) Amyloid and the gut. Dig Dis 15:155–171PubMedCrossRef

Lowenstein J, Gallo G (1970) Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med 282:128–132PubMedCrossRef

Masaki Y, Sugai S (2004) Lymphoproliferative disorders in Sjogren’s syndrome. Autoimmun Rev 3:175–182PubMedCrossRef

McAlpine JC, Fuller A (1964) Localised laryngeal amyloidosis, a report of a case with a review of the literature. J Laryngol Otol 78:296–314PubMedCrossRef

McIlwain JC, Shepperd H (1986) Laser treatment of promary amyloidosis of the larynx. J Laryngol Otol 100:1079–1080PubMedCrossRef

Merlini G, Dispenzieri A, Sanchorawala V et al (2018) Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primer 4:38

Mitrani M, Biller H (1985) Laryngeal amyloidosis. Laryngoscope 95:1346–1347PubMedCrossRef

Miyamoto T, Kobayashi T, Makiyama M et al (1999) Monoclonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. J Clin Pathol 52:464–467PubMedPubMedCentralCrossRef

Moore A, Kramer MR, Silvern D et al (2018) Endobronchial brachytherapy – a novel approach for the management of airway amyloidosis. Brachytherapy 17:966–972PubMedCrossRef

Mumford AD, O’Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M (2000) Bleeding symptoms and coagulation abnormalities in 337 patients with AL amyloidosis. Br J Haematol 110:454–460PubMedCrossRef

Murdoch IEST, Moseley I, Hawkins PN (1996) Primary localised amyloidosis of the orbit. Br J Ophthalmol 80:1083–1086PubMedPubMedCentralCrossRef

Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M (1999) Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology 38:499–503PubMedCrossRef

Neinhuis DM, Prakash UB, Edell ES (1990) Tracheobronchopathia osteochondroplastica. Ann Otol Rhinol Laryngol 99:689–694CrossRef

Neuner GA, Badros AA, Meyer TK, Nanaji NM, Regine WF (2012) Complete resolution of laryngeal amyloidosis with radiation treatment. Head Neck 34:748–752PubMedCrossRef

Nugent AM, Elliott H, McGuigan JA, Varghese YG (1996) Pulmonary amyloidosis: treatment with laser therapy and systemic steroids. Respir Med 90:433–435PubMedCrossRef

O’Regan A, Felon HM, Beamis JF, Steele MP, Skinner MD, Berk J (2000) Tracheobronchial amyloidosis: the Boston university experience from 1984 to 1999. Medicine (Baltimore) 79:69–79CrossRef

Özkan F, Khan AM, Freitag L, Montag M, Hahn S, Berliner PJ, Darwiche K (2014) Hemoptysis in primary pulmonary amyloidoma treated with intrabronchial arterial coiling. Am J Respir Crit Care Med 190:1311–1314CrossRef

Palladini G, Sachchithanantham S, Milani P et al (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126(5):612–615PubMedCrossRef

Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E (1997) Amyloid P component. A critical review. Amyloid 4:274–295CrossRef

Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A (2003) Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 260:349–354PubMedCrossRef

Puchtler H, Sweat F, Levine M (1962) On the binding of Congo red by amyloid. J Histochem Cytochem 10:355–364CrossRef

Rokitansky K (1842) Handbuch der pathologischen Anatomie, 3. Aufl. Braumüller & Seidel, Wien, S 311, 384, 424

Rubinow ACB, Cohen AS, Rigden BG, Brody JS (1978) Localized amyloidosis of the lower respiratory tract. Am Rev Respir Dis 118:603–611PubMed

Sachchithanantham S, Wechalekar AD (2013) Imaging in systemic amyloidosis. Br Med Bull 107:41–56PubMedCrossRef

Sakula A (1968) Tracheobronchopathia osteochondroplastica: its relationship to primary tracheobronchial amyloidosis. Thorax 23:105–110PubMedPubMedCentralCrossRef

Schattner A, Varon D, Green L, Hurwitz N, Bentwich Z (1986) Primary amyloidosis with unusual bone involvement: reversibility with melphalan, prednisone, and colchicine. Am J Med 86:347–348CrossRef

Sezer O, Schmid P, Shweigert M (1999) Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 23:967–969PubMedCrossRef

Shah PL, Gillmore JD, Copley SJ (2002) The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis 19:134–142PubMed

Siddachari R, Chaukar DA, Pramesh CS, Naresh KN, de Souza CE, Douzak AK (2005) Laryngeal Amyloidosis. J Otolaryngol 34:60–63PubMedCrossRef

Sipe JD, Cohen AS (2000) Review: history of the amyloid fibril. J Struk Biol 130:88–98CrossRef

Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P (2014) Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21:221–224

Smith R, Hutchins GM, Moore GW, Humphrey RL (1979) Type and distribution of pulmonary parenchymal and vascular amyloid. Am J Med 66:96–104. (Correlation with cardiac amyloid)PubMedCrossRef

Tan SY, Pepys MB (2002) Amyloidosis (1994). Histopathology 25:403–414CrossRef

Tirzaman O, Wahner-Roedler DL, Malek RS, Sebo TJ, Li CY, Kyle RA (2000) Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. Mayo Clin Proc 75:1264–1268PubMedCrossRef

Urban BA, Fishman EK, Goldman SM (1993) CT evaluation of amyloidosis: spectrum of disease. Radiographics 13:1295–1308PubMedCrossRef

Virchow R (1854) Ueber eine im Gehirn und Rückenmark des Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose. Virchows Arch Path Anat 6:135–138

Walker P, Courey MS, Ossoff R (1996) Staged endoscopic treatment of laryngeal amyloidosis. Otolaryngol Head Neck Surg 114:801–805PubMed

Wechalekar AD, Gillmore JD, Bird J et al (2015) Guidelines on the management of AL amyloidosis. Br J Haematol 168:186–206. (BCSH Committee)PubMedCrossRef

Woollons A, Black MM (2001) Nodular localized primary cutaneous amyloidosis: a long-term follow-up study. Br J Dermatol 145:105–109PubMedCrossRef

Yamada T (1999) Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 37:381–388PubMedCrossRef

Zamora AC, White DB, Sykes AMG et al (2016) Amyloid-associated cystic lung disease. Chest 149:1223–1233PubMedCrossRef

Zatloukal P, Bezdiek P, Schimonova M, Tesarova P, Slovakaova A (1998) Waldenstrom’s macroglobulinemia with pulmonary amyloidosis. Respiration 65:414–416PubMedCrossRef

Titel: Amyloidose
verfasst von: Lars Hagmeyer
Ute Hegenbart
Stefan Schönland
Björn Kleibrink
Helmut Teschler
Verlag: Springer Berlin Heidelberg
Buch: Seltene Lungenerkrankungen
Print ISBN: 978-3-662-63650-3

Electronic ISBN: 978-3-662-63651-0

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-63651-0_21

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

21. Amyloidose

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin